Hawk associates | cHrysler Building | 405 lexington ave, 26tH floor | new york, ny 10174 | tel: 212.541.2465 227 atlantic Boulevard | key largo | florida | 33037 | tel: 305.451.1888

Company DescriptionManhattan Scientifics Inc. develops and nurtures financially promising technology companies with global application potential. The company and its affiliates own significant intellectual property and patents in high-strength metals and early cancer detection technologies.

The company’s business model is to identify significant technologies, acquire the rights and take appropriate steps to commercialize and through partnerships with manufacturers and licensees bring products to market that will create profit for shareholders.

Manhattan Scientifics has enjoyed a special informal relationship and a successful history in tech-transfer with the Los Alamos National Laboratory (LANL) and the Sandia National Laboratory (SNL).

Lines of BusinessNanomedicine – Through the acquisition of Senior Scientific, founded by Dr. Edward Flynn, Manhattan Scientifics gained the rights to breakthrough nano technology and intellectual property related to the detection and monitoring of cancer and other d iseases.The technology uses nontox ic , superparamagnetic nanoparticles to specifically target cancer cells. It has demonstrated 1000X better sensitivity than current techniques used to find cancer. The next generation of this technology is expected to provide another 1000X increase in sensitivity.

Advanced Materials – Manhattan Scientifics owns exclusive rights to the key patents and IP portfolio to produce and market NanoTitanium and other ultra fine grain nano-structured metals developed at the Los Alamos National Laboratory. The company acquired Metallicum along with its patented rights for new ultra fine grain metals that may advance the transportation and medical device industry,

NanoTitanium is highly compatible with bone and is thought to provide stronger, faster bonding with improved strength, biocompatibility, longer life and improved wear and tear.

It is believed NanoTitanium also could profoundly impact fuel economy. The technology is expected to tr im thousands of pounds from airplanes and hundreds of pounds from cars without sacrificing structural strength or adding significant cost.

In February 2015, the company reaquired all of its rights to its nano-structured metals technology from its former licensee whose strategic priorities changed. The agreement included a one-time $8M payment to MHTX and assignment of all related IP as well as ownership of various ECAP equipment. The company is pursuing severa l medica l and indust r ia l applications of the technology through strategic relationships.

May  8,  2015

Investment Profile OTCQB: MHTX

OTCQB: MHTX

Closing Price (5/7/15) $0.062 Market Cap. $32.09 mil 52-Week Range $0.06 - 0.18 Avg, Daily Volume 270,935 Basic Shares 449 mil . Est. Public Float 337 mil Insider Ownership 19.21% Fiscal Year End Dec. 31

Manhattan Scientifics To Market “Potentially Disruptive” Early Cancer Detection and Treatment Technology with $2.5M Investment Commitment.

Reacquires Nano-Structured Metals Technology. Receives $8M Cash.

Highlights

05/8/15 MHTX issues letter from new president of Senior Scientific Subsidiary.

3/25/15 Marvin Maslow returns as Chairman of the Board. Company retains investment bank.

02/18/2015 MHTX reacquires nano-structured metals technology and receives an $8 million one time payment.

1/14/15 Manhattan Scientif ics names Robert R. Proux as president and chief operating officer of its Senior Scientific subsidiary.

10/02/14 MHTX issues shareholder update. Company expects its technology to e m e r g e a s n e w i m p o r t a n t evolutionary step in cancer diagnosis.

06/10/2014 MHTX delivers initial break-through cancer measuring instrument to M.D. Anderson Cancer Center in Houston, TX.

1/27/2014 MHTX announces collaboration with MD Anderson Cancer Center

The information contained herein is believed to be accurate and is based upon sources which are considered reliable but are not guaranteed by Hawk Associates or the company mentioned. This information is subject to change without notice. Hawk Associates is not a registered broker dealer. Neither Hawk Associates nor the company mentioned assumes any responsibility for the information contained herein. The company featured in this report is a client of Hawk Associates, Inc. This does not represent an offer to buy or sell any security. This profile is protected by applicable copyright laws. No permission is granted to copy, distribute, modify, or post any text, graphics, design or logos.

Investment Profile OTCQB: MHTX

Edward R. Flynn, Ph.D. and his company Senior Scientific LLC. His breakthrough technology focuses on the emerging field of nanomedicine with emphasis on the early detection and localization of cancer and other diseases, providing image-guided therapy for treatment.

Early detection of cancer can be critical to effective treatment. Current mammography cannot detect a breast cancer tumor until it has grown to over ten million cells. Dr. Flynn's technology has proven the ability to detect breast cancer tumors while they are only 1% that large, resulting in an hundred-fold increase in imaging sensitivity and early detection.

When fully developed and commercialized, Dr. Flynn's biomagnetic -based system will be 100% radiation free, unlike current radiation-based mammogram tests. His approach uses sophisticated magnetic field sensors to measure extremely small magnetic fields emitted by magnetic nanoparticles that have been injected into the body and targeted specifically toward cancer cells. The method yields high contrast images of tumors compared to normal cells. This makes it possible to identify and image tiny clusters of cancer cells enabling detection of cancer at substantially earlier stages than is presently possible.

The OutlookThe company is working with MD Anderson Cancer Center to advance, demonstrate and validate a breakthrough technology developed by Edward R. Flynn, PhD, for the very early detection of cancer. Following two years of informal collaboration, MD Anderson and Senior Scientific have now inked a deal to formally collaborate on this technology seeking a path toward FDA approval and human d i a g n o s t i c a p p l i c a t i o n s . U n d e r t h e collaboration agreement, Senior Scientific will supply a next generation instrument to MD

Anderson during the first quarter of 2014. MD Anderson will be the first institution to use the new technology in its cancer research programs.

MHTX continues its role as pioneer in the fields of nano technology with medical applications. It now has three issued U.S. patents, four international PCT patents and multiple U.S. utility applications pending along with national phase applications in 10 other countries.

In April 2013, the company announced that it had received a $2.5 million commitment from a prestigious private investment group to build

the first generation of its advance cancer detection devices. The group is led by one of the most successful investors in the history of Wall Street.

In February 2015, the company reacquired the rights to its nano-structured metals technology and received $8 in cash and added $10 million in non-cash assets to the company’s balance sheet.

In March 2015, the company announced it has retained investment bank Imperial Capital to explore strategic alternatives for its Metallicum Division saying it believes its metal technology is more vital than ever before.

Website InformationCopies of MHTX press releases, current price quotes and other valuable information for investors may be found at www.mhtx.com and www.hawkassociates.com.

Management TeamCEO/Chairman - Emmanuel (Manny) Tsoupanarias

Non-executive Chairman - Marvin Maslow

Director, Special legal counsel - Larry Schatz, Esq.

Director - Leonard Friedman, Esq.

Director - Frank Georgiou

Director - Chris Theoharis

Scientific Advisory BoardDr. Terry Lowe - Co-inventor of the nano-structured metals process, president and chief scientist for the Metallicum unit of MHTX

Dr. Martin Cooper - 28 years chief technical officer with Motorola. “Father” of cellular telephone.

Dr. Arthur Kaufman - Co-founder of H-Power, a leader in the hydrogen fuel cell industry.

Donald J. Sandstrom - 42 years with Los Alamos National Laboratory. Materials Science Technology Division Leader.

Dr. Henry Rack - Professor of Materials Science & Engineering at Clemson University

Risk Factors • Access to sufficient capital to bring

product to market; to defend its patents; to surpass its competitors..

• Ability to recruit additional senior management.

• Potential technical obsolescence.

• Numerous well-capitalized competitors.